THALES
18.9.2023 14:01:30 CEST | Business Wire | Press release
Thales, the leading global technology and security provider, today announced the launch of CipherTrust Cloud Key Management's Hold Your Own Key (HYOK) in Oracle Cloud Infrastructure (OCI) across all 45 Oracle Cloud Regions—including the recently launched Oracle EU Sovereign Cloud—and OCI’s other distributed cloud offerings. To help meet continued customer demand and the accelerated growth of the OCI platform, HYOK will help OCI customers achieve their data sovereignty and other compliance objectives more easily by encrypting data in OCI with keys that are controlled and managed outside of the cloud platform. The new HYOK capabilities expand on existing support for Bring Your Own Key (BYOK) in OCI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918263668/en/
©Thales
According to the 2023 Thales Cloud Security Study, while the world has become cloud-first, operational complexity in cloud environments remains a significant obstacle for organizations. Overall, cloud security awareness has improved, but concerns around securing data are also rising, with over half (55 percent) of security professionals indicating it’s more complex to manage data in the cloud than it is in on-premises environments. As a result, as cloud usage grows, organizations need a new way to effectively secure cloud environments.
The CipherTrust Cloud Key Management integration enables OCI customers to store and manage their encryption keys outside OCI in a virtual or physical appliance that is entirely under their control and outside of the cloud. Customers can also localize their encryption keys wherever they choose and maintain control of their encrypted data in cloud environments. This approach helps address some of the key privacy and data sovereignty requirements organizations face while making it easier to demonstrate compliance to regulators.
The availability of the Thales external key management solution can help accelerate the move of sensitive data into Oracle Cloud Regions by storing the key in a location that is different than the encrypted data. This enables customers to maintain the same process for managing and controlling encryption keys, whether those keys are used on-premises or in the cloud
Thales CipherTrust Cloud Key Management, the industry-leading multi-cloud encryption key lifecycle management solution, alleviates operational barriers across clouds and hybrid environments. The HYOK functionality gives OCI customers the external key management capabilities necessary to navigate today’s cloud-driven landscape and remain in charge of their data, not just in OCI, but across other cloud providers.
Todd Moore, Vice President of Data Security Products at Thales: “Businesses are increasingly shifting away from legacy on-premises deployments and need assistance in moving their data to the cloud while maintaining security and compliance. As the industry leader in external key management, we’re proud to be the first to support HYOK features in OCI, equipping OCI customers with the necessary solutions to be successful in this journey. To further this best-in-class experience for our combined customer base, Thales is also the first supporting vendor for Oracle EU Sovereign Cloud initiatives.”
Jeppe Larsen, Senior Vice President, OCI Security and Identity at Oracle: “We’re dedicated to making OCI the most trusted cloud for security-sensitive workloads, including those in highly regulated regions and industries. Oracle EU Sovereign Cloud helps customers operating in Europe to address their data sovereignty requirements, and the HYOK integration with Thales enhances that offering. In addition, this partnership and integration will benefit U.S. customers in regulated industries such as financial services by enabling them to take full advantage of OCI, with the privacy and security benefits of HYOK from Thales.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion. |
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918263668/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom